Saturday, December 2, 2017

An Integrated BioSci Research On Melinta Therapeutics - A Newly Merged Firm To Tackle Deadly Infectious Diseases

Summary


  • Drug resistance from superbugs is an increasingly alarming problem.
  • The recently FDA-approved antibiotic, delafloxacin (Baxdela) to launch promptly, for the treatment of serious skin infections.
  • Robust pipeline to increase the shots on goal in finding a blockbuster.
  • Formerly a private bioscience, Melinta recently merged with Cempra to form the new company. The cash position is highly robust to fund future innovation.
  • This is the sample of the Integrated BioSci research that we published exclusively for Integrated BioSci Investing subscribers.




In the past month, shares of Melinta Therapeutics (NASDAQ:MNLT) - a bioscience firm, focusing on the development and commercialization of antibiotics to treat infectious diseases - increased by $0.45 to trade at $16.95 (as of Dec. 1, 2017) for over 44% profits. While we mostly focus on cancer developers like the CAR-T firms, i.e. Kite Pharma (NASDAQ:KITE) or Gilead Sciences (NASDAQ:GILD), we also feature stellar biosciences that hold promising molecules. Companies that we're covering tend to deliver robust values for shareholders as well as hopes for patients. That being said, Melinta certainly fits the tab. In this research, we’ll elucidate the pipeline prospects, the recent acquisition, upcoming launch (as well as to touch upon the financial analysis and pertinent risks).


Figure: Melinta stock chart. (Source: StockCharts)

Author’s Notes: The full Integrated BioSci Research is available to subscribers of our marketplace service, Integrated BioSci Investing (where we also deliver in-depth consulting and key market-moving catalyst events).